HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
Clinical trial NCT03685708 · COMPLETED
Trial details
- NCT number
- NCT03685708
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-07
- Primary completion
- 2020-12-16
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.